Sang Hoon Chun
Overview
Explore the profile of Sang Hoon Chun including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
375
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jang S, Lee Y, Chun S, Park J, Park K, Chang H, et al.
Head Neck
. 2025 Jan;
PMID: 39835419
Background: This study analyzed the clinical features of patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), who developed progressive disease (PD) after immune checkpoint inhibitor...
2.
Kang J, Lee K, Huh S, Shin S, Kim I, Hwang I, et al.
Oncologist
. 2024 Jul;
29(11):e1593-e1603.
PMID: 39028339
Background: The physical dependence on prescription opioids among cancer survivors remains an under-investigated area, with a scarcity of well-designed prospective studies. Methods: This single-arm, phase-2 clinical trial in Korea assessed...
3.
Kim M, Shim H, Kim S, Lee I, Kim J, Yoon S, et al.
J Pathol Transl Med
. 2024 Jul;
58(4):147-164.
PMID: 39026440
In recent years, next-generation sequencing (NGS)-based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope...
4.
Lee C, Lee H, Kim S, Nam S, Lee G, Yang K, et al.
Cell Death Dis
. 2024 Apr;
15(4):274.
PMID: 38632244
Accumulating evidence demonstrates that the activity regulation of ELK3, a member of the E26 transformation-specific oncogene family, is critical to regulating cell proliferation, migration, and survival in human cancers. However,...
5.
Kim M, Shim H, Kim S, Lee I, Kim J, Yoon S, et al.
Cancer Res Treat
. 2023 Dec;
56(3):721-742.
PMID: 38037319
In recent years, next-generation sequencing (NGS)-based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope...
6.
Lee K, Cho B, Ahn M, Lee Y, Lee Y, Lee J, et al.
Cancer Res Treat
. 2023 Jul;
56(1):48-60.
PMID: 37402411
Purpose: This subgroup analysis of the Korean subset of patients in the phase 3 LASER301 trial evaluated the efficacy and safety of lazertinib versus gefitinib as first-line therapy for epidermal...
7.
Kim S, Chun S, Jin J, Gweon T, Lee H, Jin M, et al.
Korean J Clin Oncol
. 2023 Mar;
17(2):126-130.
PMID: 36945674
There have been several reports of complications of small bowel lymphoma, such as bleeding, obstruction, and perforation, often require emergency surgery. It is hardly showed complications of bleeding and wound...
8.
Kim S, Chun S, Kim J, Kim S, Lee B, Jung C, et al.
Korean J Clin Oncol
. 2023 Mar;
16(1):57-62.
PMID: 36945301
Recent data showed that DNA mismatch repair deficiency can be a predictive biomarker for a favorable response of immune checkpoint inhibitors regardless of tumor type due to give rise to...
9.
MicroRNA-769-3p Acts as a Prognostic Factor in Oral Squamous Cell Cancer by Modulating Stromal Genes
Lee H, Chun S, Moon S, Yoon J, Won H, Hong S, et al.
Cancers (Basel)
. 2022 Sep;
14(18).
PMID: 36139534
miR-769-3p expression is suppressed in the stromal subtype of head and neck squamous cell carcinoma (HNSCC); however, its role in stromal HNSCC has not been fully elucidated. To investigate the...
10.
Kim S, Kim J, Lee J, Moon S, Jo S, Bae D, et al.
Biochim Biophys Acta Mol Basis Dis
. 2022 Aug;
1868(11):166516.
PMID: 35940382
Immune checkpoint inhibitors (ICIs) offer improved survival for patients with advanced malignant melanomas. However, only a subset of these patients exhibit an objective response rate of 10-40 % with ICIs....